|MDACC Study No:||2010-0509 (clinicaltrials.gov NCT No: NCT01211691)|
|Title:||Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of Part 1 (Dose Escalation) of this clinical research study was to |
find the highest tolerable dose of KB004 that can be given safely to patients
with leukemia or another type of blood cancer. No more participants will be
enrolled on Part 1 at MD Anderson.
The goal of Part 2 (Cohort Expansion) of the study is to further study the
activity of KB004 in people with the same blood cancer and whose cancers
express EphA3. The safety of KB004 will also be studied. All new participants
at MD Anderson will be enrolled in Part 2 of the study.